Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

VEP 2017: How to treat CML in 2017?

We are pleased to make available a new series of presentations on various aspects of CML management that were first presented at the 22nd Meeting of the European Hematology Association (EHA) in Madrid in 2017. Modules currently featured include; how to treat CML in 2017, factors affecting clinical decision making in relapsed and refractory CP-CML patients and treatment outcomes of bosutinib from real-world data. 

 We are very grateful for the support of Brandcast media to produce these webstreams.
EHA Andreas Hochhaus

 

 

  

         

 

How to treat CML in 2017?
Andreas Hochhaus, Universitätsklinikum Jena, Germany 

  • Objectives of treatment optimization
  • Choice of initial therapy
  • Clinical data on 1st and 2nd generation TKI's
  • Comorbidities in CML at diagnosis
  • Main adverse events of TKI's
  • ELN recommendations for monitoring of first-line TKI therapy
  • Recommendations for switch: CP-CML
  • Management of blast crisis
  • Limitations of TKI therapies
  • Discussion: are we ready for routine stopping procedure?
  • Recommendations on CML management 2013 - 2017

This presentation is adapted from the one presented during the CML educational session at EHA. It lasts around 30 minutes.

VEP Modern Diagnostics: Biomarkers

Deborah White                                                                

 

 

 

Biomarkers and response monitoring beyond PCR?
Deborah White - SAHMRI, University of Adelaide

  • Predictive biomarkers
  • Cytokines, growth factors and chemokines: TGF and IL6
  • KIR2DS1 genotype and inferior cytogenetic response: SPIRIT1
  • CIP2A and response
  • Imatinib drug levels and compliance
     

VEP Modern Diagnostics: Value of cytogenetic analysis in CML

-- Virtual Education Program: 2016 Edition

We are pleased to make available a new series of presentations on modern diagnostics in CML that were first presented at the 'Clinical Symposium on Modern Diagnostics' during the 18th John Goldman Conference on CML in Houston in 2016. Modules currently featured include; The role of cytogenetic monitoring in CML management, Molecular monitoring in CML, Mutation screening and Biomarkers and response monitoring beyond PCR. 

 

Jorge Cortes 2013                          

 

The role of cytogenetic monitoring in CML management
Jorge Cortes - MD Anderson Cancer Center, University of Texas

  • Cytogenetic evaluation in CML
  • Cytogenetic clonal evolution
  • Additional chromosomal abnormalities in CML
  • Response to TKI by additional chromosomal abnormalities
  • Cytogenetic abnormalities in PH(1) metaphases
  • Additional cytogenetic abnormalities in CML-CP on TKI
  • Additional cytogenetic abnormalitites in 5q-MDS
     

VEP Modern Diagnostics: Mutation Screening

 

 We are very grateful for the support of Brandcast media to produce this web stream
VEP Soverini

 

 

  

         

 

 

Mutation Screening:
What is standard of care today and the role of new modalities
Simona Soverini, University of Bologna, Italy 

  • BCR-ABL kinase domain (KD) mutation for optimal patient management
  • When to perform BCR-ABL KD mutation analysis
  • How to perform BCR-ABL KD mutation analysis
  • BCR-ABL KD mutation screening: key issues
  • Next-generation sequencing (NGS): applications
  • NGS for routine BCR-ABL mutatation testing: when?
  • NGS for routine BCR-ABL mutation screening: hurdles
  • Conclusions

VEP Modern Diagnostics: Molecular Monitoring in CML

 

 We are very grateful for the support of Brandcast media to produce this web stream
VEP Müller

 

 

  

         

 

 

Molecular monitoring in CML - getting to a safe place
Martin C. Müller, Institute for Hematology and Oncology (IHO) and Medical Faculty Mannheim, University of Heidelberg, Germany 

  • What do we consider safe?
  • Cytogenetic and molecular monitoring: European LeukemiaNet recommendations
  • Molecular monitoring every 3 months - enough for all patients?
  • Achieving deep remissions
  • Definitions of molecular response
  • Compliance check
  • Conclusions

Welcome to the iCMLf Virtual Education Program

This Virtual Education Program, provided by the iCMLf offers a series of webcast presentations from leading hematologists.

These presentations provide updated information on treatment advances and best practice management of CML, including disease monitoring and new therapies. The sessions specifically address issues of CML care in countries with limited access to monitoring and supplemental treatments.

Modules des langues français

Módulos en español